Islet autoantibodies in clinically diagnosed type 2 diabetes: Prevalence and relationship with metabolic control (UKPDS 70)

Diabetologia

Volumn 48, Issue 4, 2005, Pages 695-702

  Davis, T M E ^a   Wright, A D ^b   Mehta, Z M ^c   Cull, C A ^c   Stratton, I M ^c   Bottazzo, G F ^d   Bosi, E ^e   MacKay, I R ^f   Holman, R R ^c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c CHURCHILL HOSPITAL   (United Kingdom)

^d BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f MONASH UNIVERSITY   (Australia)

Author keywords

GADA; Glycaemia; ICA; Type 2 diabetes; UKPDS

Indexed keywords

GLUTAMATE DECARBOXYLASE ANTIBODY; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IA ANTIBODY; INSULIN; METFORMIN; PANCREAS ISLET CELL ANTIBODY; SULFONYLUREA;

ADULT; AGED; ANTIBODY TITER; ARTICLE; BLOOD PRESSURE MEASUREMENT; CAUCASIAN; CELL FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DIET THERAPY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH CARE POLICY; HUMAN; HYPERGLYCEMIA; INSULIN SENSITIVITY; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SYMPTOMATOLOGY; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AUTOANTIBODIES; BLOOD GLUCOSE; BODY WEIGHT; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DIET THERAPY; FEMALE; GLUTAMATE DECARBOXYLASE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; INSULIN; LIPOPROTEINS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 17844393918     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-005-1690-x     Document Type: Article

References (25)

1. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR (1993) Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 42:359-362
2. Niskanen LK, Tuomi T, Karjalainan J, Groop LC, Uusitupa MIJ (1995) GAD antibodies in NIDDM. Diabetes Care 18:1557-1565
3. UKPDS Group (1997) UKPDS 25: clinical value of ICA and GADA in predicting insulin requirement in patients with newly diagnosed NIDDM at different ages. Lancet 350:1288-1293
4. Rosenbloom AL (2003) Obesity, insulin resistance, b-cell autoimmunity, and the changing clinical epidemiology of childhood diabetes. Diabetes Care 26:2954-2956
5. UKPDS Group (1991) UK prospective diabetes study VIII: study design, progress and performance. Diabetologia 34:877-890
6. UKPDS Group (1998) Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
7. UKPDS Group (1998) UK Prospective Diabetes Study 24: relative efficacy of sulfonylurea, insulin and metformin therapy in newly diagnosed non-insulin dependent diabetes with primary diet failure followed for six years. Ann Intern Med 128:165-175
8. Bonifacio E, Bingley PJ, Shattock M et al (1990) Quantification of islet-cell antibodies and prediction of insulin dependent diabetes. Lancet 147-149
9. Verge CF, Stenger D, Bonifacio E et al (1998) Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: combinatorial islet autoantibody workshop. Diabetes 47:1857-1866
10. Bonifacio E, Lampaspona V, Genovese S, Ferrari M, Bosi E (1995) Identification of protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetes-related 37/40K autoantigen and a component of islet cell antibodies. J Immunol 155:5419-5426
11. Bonifacio E, Lampaspona V, Bingley PJ (1998) IA-2 (islet cell antigen 512) is the primary target of humoral autoimmunity against Type 1 diabetes-associated tyrosine phosphate autoantigens. J Immunol 161:2648-2654
12. UKPDS Group (1994) UK prospective diabetes study XI: biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabet Med 11:534-544
13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
14. Levy J, Matthews D, Hermans M (1998) Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21:2191-2192
15. Expert Panel on Detection and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the national cholesterol education program (NCEP). JAMA 285:2486-2497
16. Gottsater A, Ahmed M, Lilja B, Fernlund P, Sundkvist G (1996) Islet cell antibodies at diagnosis, but not leanness, relate to a better cardiovascular risk factor profile 5 years after diagnosis of NIDDM. Diabetes Care 19:60-63
17. Willis JA, Scott RS, Brown LJ et al (1996) Antibodies against glutamic acid decarboxylase in newly diagnosed adult-onset diabetes mellitus. Diabetes Res Clin Pract 33:89-97
18. Bingley PJ, Bonifacio E, Mueller P (2003) Diabetes antibody standardization program: first assay proficiency evaluation. Diabetes 52:1128-1136
19. Hosszufalusi N, Vatay A, Rajczy K et al (2004) Similar genetic features and different islet cell autoantibodies in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression. Diabetes Care 26:452-457
20. UKPDS Group (2000) Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35). BMJ 321:405-412
21. Lohmann T, Kellner K, Verlohren HJ et al (2001) Titre and combination of ICA autoantibodies to glutamic acid and decarboxylase discriminate two clinically distinct types of latent autoimmune diabetes in adults (LADA). Diabetologia 44:1005-1010
22. Davis TME, Zimmett P, Davis WA, Fida S, Bruce D, Mackay I (2000) Autoantibodies to glutamic acid decarboxylase in diabetic patients from a multi-ethnic Australian community. Diabet Med 17:667-674
23. Bosi E, Cull CA, Bonifacio E et al (2004) IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting as type 2 diabetes. Diabetologia DOI:10.1007/s00125-005-1691-9
24. UKPDS Group (1998) Risk factors for coronary artery disease in non-insulin dependent diabetes (UKPDS 23). BMJ 316:823-828
25. Tuomi T, Carlsson A, Isomaa B et al (1999) Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 48:150-157